Parsian Pharmaceutical

Parsian Pharmaceutical is an Iranian pharmaceutical company specialized in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. Established in 2008 and headquartered in Tehran, the company focuses on critical therapeutic areas including oncology, diabetes, cardiovascular diseases, and autoimmune disorders. Its portfolio includes over 50 APIs, with notable products such as Letrozole for breast cancer and ongoing development in JAK inhibitors and S1P receptor modulators like Ozanimod. Parsian Pharmaceutical operates through its manufacturing facilities and maintains a strong presence in the domestic Iranian market while seeking international partnerships for distribution and R&D. The company is also involved in computational drug repurposing research, particularly in the field of antivirals.